{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:11:30Z","timestamp":1794978690305,"version":"4.9.1"},"reference-count":29,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Talquetamab is the first approved GPRC5D-targeting bispecific antibody for the treatment of relapsed\/refractory multiple myeloma (RRMM), based on results from the phase 1\/2 MonumenTAL-1 study. We report the infection profile among patients treated with talquetamab in MonumenTAL-1. Patients with triple-class exposed RRMM received subcutaneous talquetamab 0.4 mg\/kg weekly or 0.8 mg\/kg every other week (EOW). Patients with prior T-cell redirection therapy (TCR) were included in a separate cohort and received either schedule. Infections (graded by Common Terminology Criteria for Adverse Events v4.03) were managed per local guidelines. Patients received talquetamab (N = 339) with a median follow-up of 18.8 (weekly; n = 143), 12.7 (EOW; n = 145), and 14.8 (prior TCR; n = 51) months. Infections occurred in 58.7%, 66.2%, and 72.5% of patients, respectively; most common were respiratory infections, including COVID-19. Grade 3\/4 infections occurred in 21.7% (weekly), 15.9% (EOW), and 27.5% (prior TCR) of patients, onset most common in cycles 1\/2. Opportunistic infections were low (3.5%, 5.5%, and 5.9%, respectively). Five patients died due to infections. Neutrophil levels recovered at cycle 2 and were maintained throughout treatment. B-cell levels remained stable in early cycles, with notable increases at cycle 7. Immunoglobulin G levels recovered after cycle 3 and increased through cycle 17. Few patients started IV immunoglobulin following talquetamab (9.8% [weekly], 6.9% [EOW], and 5.9% [prior TCR]). Patients treated with talquetamab demonstrated relatively low rates of grade 3\/4 infections and preservation of humoral immunity, distinguishing talquetamab as an important and potentially less immunosuppressive, novel treatment option for patients with RRMM. These trials were registered at www.clinicaltrials.gov as #NCT03399799 and #NCT04634552.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016613","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:56:07Z","timestamp":1756306567000},"page":"5752-5762","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"first","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences Winthrop P. Rockefeller Institute, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"2Navarra Institute for Health Research (IdiSNA), University Hospital of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brea","family":"Lipe","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Lavi","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"6Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Van Oekelen","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Skerget","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cortes-Selva","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-4341","authenticated-orcid":false,"given":"Raluca","family":"Verona","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Hilder","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Masterson","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Campagna","sequence":"additional","affiliation":[{"name":"9Johnson & Johnson, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Khedkar","sequence":"additional","affiliation":[{"name":"10Johnson & Johnson, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[{"name":"11Johnson & Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Kane","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen S.","family":"Gray","sequence":"additional","affiliation":[{"name":"10Johnson & Johnson, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6583-9243","authenticated-orcid":false,"given":"Ibrahim","family":"Saber","sequence":"additional","affiliation":[{"name":"10Johnson & Johnson, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[{"name":"8Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"12Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) Program, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"2","key":"2025112508562526900_bib1","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025112508562526900_bib2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.7150\/jca.29993","article-title":"Multiple myeloma: what do we do about immunodeficiency?","volume":"10","author":"Li","year":"2019","journal-title":"J Cancer"},{"issue":"8","key":"2025112508562526900_bib3","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025112508562526900_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2025112508562526900_bib5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/17474086.2019.1682545","article-title":"What are the implications of cost for myeloma therapy?","volume":"12","author":"Xu","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2025112508562526900_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"16","key":"2025112508562526900_bib7","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1182\/bloodadvances.2023010856","article-title":"Beyond BCMA: newer immune targets in myeloma","volume":"8","author":"Tan","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2025112508562526900_bib8","doi-asserted-by":"crossref","first-page":"ofac574","DOI":"10.1093\/ofid\/ofac574","article-title":"Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis","volume":"9","author":"Vassilopoulos","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2025112508562526900_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"10","key":"2025112508562526900_bib10","doi-asserted-by":"crossref","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"S91","key":"2025112508562526900_bib11","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S2152-2650(21)02229-1","article-title":"P-095: normal human tissue expression of G-protein coupled receptor 5D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues","volume":"21","author":"Goldsmith","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"485","key":"2025112508562526900_bib12","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"2025112508562526900_bib13","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2025112508562526900_bib14","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112508562526900_bib15","volume-title":"Prescribing information","author":"Janssen Biotech Inc. TALVEY (talquetamab-tgvs)","year":"2023"},{"key":"2025112508562526900_bib16","unstructured":"European Medicines Agency\n          . TALVEY (talquetamab). 2023. Accessed 26 February 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/talvey."},{"issue":"16 suppl","key":"2025112508562526900_bib17","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025112508562526900_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025112508562526900_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2025112508562526900_bib20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"suppl 1","key":"2025112508562526900_bib21","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2023-187755","article-title":"Mechanisms of resistance and relapse with talquetamab in patients with relapsed\/refractory multiple myeloma from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"2025112508562526900_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.HS9.0000843612.41180.42","article-title":"S180: RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: preliminary results from a first-in-human trial","volume":"6","author":"Hasselbalch Riley","year":"2022","journal-title":"HemaSphere"},{"issue":"9","key":"2025112508562526900_bib23","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"2025112508562526900_bib24","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1016\/j.ymthe.2024.07.028","article-title":"T cell-redirecting therapies in hematological malignancies: current developments and novel strategies for improved targeting","volume":"32","author":"Anderson","year":"2024","journal-title":"Mol Ther"},{"key":"2025112508562526900_bib25","first-page":"1","article-title":"CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions","volume":"41","author":"Gill","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"18","key":"2025112508562526900_bib26","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025112508562526900_bib27","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2023-182330","article-title":"Clinical outcomes of subsequent therapies in patients with relapsed\/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Sanchez","year":"2023","journal-title":"Blood"},{"issue":"16 suppl","key":"2025112508562526900_bib28","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025112508562526900_bib29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5752\/2420160\/blooda_adv-2025-016613-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5752\/2420160\/blooda_adv-2025-016613-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:56:38Z","timestamp":1764078998000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5752\/546899\/Infections-and-parameters-of-humoral-immunity-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":29,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016613","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,13]]}}}